Afynia Laboratories has secured $5 million in seed funding to develop a blood test for endometriosis, a complex condition affecting nearly 200 million individuals globally. Current diagnosis methods can take years, which delays treatments for chronic pain and fertility issues. Co-founded by Dr. Lauren Foster, the startup's innovative EndomiR test analyzes a panel of microRNA biomarkers to aid in quicker diagnosis by comparing patient's blood data to established cases. This research-driven approach aims to improve the accuracy and reliability of endometriosis diagnoses by accounting for its various presentations and stages.
Endometriosis affects nearly 200 million people worldwide, yet diagnosing the condition can take years of doctors' visits. Afynia aims to speed up the diagnosis.
Co-founder Dr. Lauren Foster emphasized the need for a panel of biomarkers to improve consistency and reliability in diagnosing endometriosis, given its complexities.
Afynia's EndomiR test detects endometriosis by analyzing microRNA in blood samples, comparing it to established cases of surgically confirmed endometriosis.
The startup’s technology seeks to facilitate faster diagnosis and treatment for endometriosis, potentially alleviating chronic pain and fertility challenges.
Collection
[
|
...
]